NEWSMore +
-
Zai Lab Announces CTA Acceptance for a Phase 3 Clinical Trial of ETX2514SUL for the Treatment of Carbapenem-Resistant Acinetobacter Infections
-
Zai Lab Supports PVW Brain Tumor Foundation to launch with Play Your Part! Benefit Concert
-
Zai Lab Announces Pricing of Public Offering of American Depositary Shares
